LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

LLY

738.06

+1.61%↑

JNJ

178.12

-0.03%↓

ABBV

209.99

-1.09%↓

UNH

320.2

+1.63%↑

NVO

54.31

-1.47%↓

Strona główna・Stock List・Bristol-Myers Squibb Co.

Bristol-Myers Squibb Co.

Closed

SectorHealthcare

46.69 -0.83

Buy Sell

Overview

Share price change

24h

Current

Min

45.85

Max

47.13

Key metrics
By Trading Economics
Income	-1.1B 1.3B
Sales	1.1B 12B
P/E Sector Avg	18.948 35.733
EPS	1.46
Dividend yield	5.25
Profit margin	10.702
Employees	34,100
EBITDA	-1.2B 3.3B

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	+8.04% upside

Dividends
By Dow Jones
Dividend yield Sector Avg	5.25% 3.13%
Next Earnings	30 paź 2025
Next Dividend date	31 paź 2025
Next Ex Dividend date	3 paź 2025

Market Stats
By TradingEconomics
Market Cap	668M 96B
Previous open	47.52
Previous close	46.69

News Sentiment

By Acuity

27%

73%

86 / 371 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bearish Evidence

N/A / 50.57 Support & Resistance

Bristol-Myers Squibb Co. Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

31 lip 2025, 11:14 UTC

Earnings

Bristol Myers Squibb Cuts Full-Year Adjusted View, But Raises Revenue Expectations on Strong 2Q

2 cze 2025, 11:48 UTC

Major Market Movers

BioNTech Sets Cancer-Drug Deal With Bristol Myers Potentially Worth More Than $11 Billion

4 sie 2025, 11:59 UTC

Earnings

BioNTech Stock Rises as Drugmaker Beats Earnings Expectations. -- Barrons.com

31 lip 2025, 11:54 UTC

Earnings

Bristol Myers Cuts Full-Year Adjusted View, But Raises Rev Estimates on Strong 2Q - Update

31 lip 2025, 10:59 UTC

Earnings

Bristol Myers Squibb 2Q Growth Portfolio Revenue Rose 18% to $6.6B >BMY

31 lip 2025, 10:59 UTC

Earnings

Bristol Myers Squibb Cuts 2025 View To Adj EPS $6.35-Adj EPS $6.65 Vs Prior View $6.70-$7.00 >BMY

31 lip 2025, 10:59 UTC

Earnings

Bristol Myers Squibb 2Q Adjusted Gross Margin 72.6% >BMY

31 lip 2025, 10:59 UTC

Earnings

Bristol Myers Squibb 2Q Adj EPS $1.46 >BMY

31 lip 2025, 10:59 UTC

Earnings

Bristol Myers Squibb 2Q International Revenue Rose 10% to $3.75B >BMY

31 lip 2025, 10:59 UTC

Earnings

Bristol Myers Squibb Raises 2025 View To Rev $46.5B-$47.5B From Prior View $45.8B-$46.8B >BMY

31 lip 2025, 10:59 UTC

Earnings

Bristol Myers Squibb: Legacy Portfolio Rev Decline Driven by Expected Continued Generic Impact Across Remainder of Legacy Portfolio, as Well as Impacts From U.S. Medicare Part D Redesign >BMY

31 lip 2025, 10:59 UTC

Earnings

Bristol Myers Squibb: In Back Half of Year, Focused on Advancing Transformational Medicines and Delivering on Our Growth Portfolio and Important Pipeline Opportunities to Shape Our Growth Trajectory >BMY

31 lip 2025, 10:59 UTC

Earnings

Bristol Myers Squibb: Raised 2025 Rev Guidance Reflecting Strength of Growth Portfolio, Better-Than-Expected Legacy Portfolio Sales in 2Q and Favorable Impact of About $200M Related to Foreign Exchange Rates >BMY

31 lip 2025, 10:59 UTC

Earnings

Bristol Myers Squibb: Latest 2Q Includes Net Impact of Loss of 57c/Shr Due to Acquired IPRD Charge Associated With BioNtech Strategic Partnership >BMY

31 lip 2025, 10:59 UTC

Earnings

Bristol Myers Squibb: Growth Portfolio Revenue Increase Primarily Driven by Immuno-Oncology Portfolio, Breyanzi, Reblozyl and Camzyos, and Reflects Continued Strength of Cobenfy >BMY

31 lip 2025, 10:59 UTC

Earnings

Bristol Myers Squibb 2Q Legacy Portfolio Rev Fell 14% to $5.67B >BMY

31 lip 2025, 10:59 UTC

Earnings

Bristol Myers Squibb 2Q Gross Margin 72.5% >BMY

31 lip 2025, 10:59 UTC

Earnings

Bristol Myers Squibb 2Q Rev $12.27B >BMY

31 lip 2025, 10:59 UTC

Earnings

Bristol Myers Beats Earnings Expectations. It's Still Optimistic About New Schizophrenia Drug. -- Barrons.com

31 lip 2025, 10:59 UTC

Earnings

Bristol Myers Squibb: Revised 2025 Adj EPS Guidance Inclusive of BioNTech Acquired IPRD Chg in 2Q >BMY

31 lip 2025, 10:59 UTC

Earnings

Bristol Myers Squibb 2Q U.S. Revenue Fell 3% to $8.52B >BMY

31 lip 2025, 10:59 UTC

Earnings

Bristol Myers Squibb 2Q EPS 64c >BMY

12 cze 2025, 14:20 UTC

Acquisitions, Mergers, Takeovers

BioNTech to Buy CureVac in $1.25 Billion Deal to Boost Its Cancer Business -- Barrons.com

13 maj 2025, 16:48 UTC

Acquisitions, Mergers, Takeovers

2seventy bio: Bristol Myers Squibb Completes Acquisition of 2seventy

12 maj 2025, 22:14 UTC

Peer Comparison

Price change

Bristol-Myers Squibb Co. Forecast

Price Target

By TipRanks

8.04% upside

12 Months Forecast

Average 50.93 USD 8.04%

High 65 USD

Low 34 USD

Based on 20 Wall Street analysts offering 12 month price targets forBristol-Myers Squibb Co. - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

20 ratings

Buy

Hold

Sell

Based on 20 analysts giving stock ratings to Bristol-Myers Squibb Co. - Dist in the past 3 months.

Technical Score

By Trading Central

N/A / 50.57Support & Resistance

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

86 / 371 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Bristol-Myers Squibb Co.

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.